Press Release
<< Back
Scientific Data on PYK2 Inhibition by VS-4718 in Multiple Myeloma Published in the Journal Blood
Additional data to be presented at the upcoming
“These data demonstrate that PYK2 is a promising therapeutic target in
multiple myeloma,” said
The paper describes the finding that patients with multiple myeloma have a higher expression of proline-rich tyrosine kinase 2 (PYK2), a member of the focal adhesion kinase (FAK) family, compared to healthy individuals, and that PYK2 plays a tumor-promoting role in myeloma progression. The FAK family is composed of just two members, FAK and PYK2, which are highly homologous. In the published study, it was demonstrated that inhibition of PYK2 led to reduction of myeloma tumor growth in vivo as well as decreased cell proliferation, cell cycle progression, and adhesion ability in vitro. In contrast, overexpression of PYK2 was shown to promote the malignant phenotype, as evidenced by enhanced tumor growth and reduced survival. The paper further describes how administration of Verastem’s FAK/PYK2 inhibitor, VS-4718, effectively inhibited myeloma cell growth in both in vitro and in vivo models.
“In addition to this work recently published by our collaborators at the
“VS-4718 is currently being evaluated in a Phase 1 dose escalation
clinical trial in patients with advanced solid tumors,” said
The full publication can be accessed online here.
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced solid tumors.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-4718
and the Company’s FAK inhibition and PI3K/mTOR programs generally, the
timeline for clinical development of the Company’s compounds, including
the new Phase 1 trial of VS-4718 in hematological malignancies, and the
structure of the Company’s planned or pending clinical trials. The words
“anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds and
preliminary or interim data from clinical trials may not be predictive
of the results or success of ongoing or later clinical trials, that data
may not be available when we expect it to be, that enrollment of
clinical trials may take longer than expected, that the Company will be
unable to successfully complete the clinical development of its
compounds, including VS-4718, that the development of the Company’s
compounds will take longer or cost more than planned, and that the
Company’s compounds will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com